Vildagliptin/Metformin Sandoz 50 mg/850 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vildagliptin/metformin sandoz 50 mg/850 mg

sandoz pharmaceuticals d.d., slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Vimetso 50 mg/1000 mg filmom obalené tablety Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vimetso 50 mg/1000 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Vimetso 50 mg/850 mg filmom obalené tablety Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vimetso 50 mg/850 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Tutecvi Combi 50 mg/850 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tutecvi combi 50 mg/850 mg

viatris limited, Írsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Tutecvi Combi 50 mg/1000 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tutecvi combi 50 mg/1000 mg

viatris limited, Írsko - metformín a vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Galvus Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Jalra Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptín - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).